Meeting: Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 63791-63792 [2015-26757]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 203 / Wednesday, October 21, 2015 / Notices
staffing, and administrative support
services for the Advisory Committee.
The charter was reissued on May 12,
2015, and will expire on May 12, 2017.
Matters for Discussion: The Advisory
Committee will continue its
deliberations from the meeting on June
4, 2015, addressing the need for
research on developmental or health
effects in children. The agenda will
include presentations on children’s
health research that has been conducted
related to exposures from the 9/11
terrorist attacks. Also, a panel of
children’s researchers will discuss
children’s research issues with the
Advisory Committee.
The agenda is subject to change as
priorities dictate.
Public Comment Sign-up and
Submissions to the Docket: To sign up
to provide public comments or to
submit comments to the docket, send
information to the NIOSH Docket Office
by one of the following means:
Mail: NIOSH Docket Office, Robert A.
Taft Laboratories, C–34, 1090 Tusculum
Avenue, Cincinnati, Ohio 45226.
Email: nioshdocket@cdc.gov.
Telephone: (513) 533–8611.
In the event an individual cannot
attend, written comments may be
submitted. The comments should be
limited to two pages and submitted
through https://www.regulations.gov by
November 27, 2015. Efforts will be made
to provide the two-page written
comments received by the deadline
below to the committee members before
the meeting. Comments in excess of two
pages will be made publicly available at
https://www.regulations.gov. To view
background information and previous
submissions go to NIOSH docket
https://www.cdc.gov/niosh/docket/
archive/docket248.html , https://
www.cdc.gov/niosh/docket/archive/
docket248–A.html, and https://
www.cdc.gov/niosh/docket/archive/
docket248–B.html.
Policy on Redaction of Committee
Meeting Transcripts (Public Comment):
Transcripts will be prepared and posted
to https://www.regulations.gov within 60
days after the meeting. If a person
making a comment gives his or her
name, no attempt will be made to redact
that name. NIOSH will take reasonable
steps to ensure that individuals making
public comments are aware of the fact
that their comments (including their
name, if provided) will appear in a
transcript of the meeting posted on a
public Web site. Such reasonable steps
include a statement read at the start of
the meeting stating that transcripts will
be posted and names of speakers will
not be redacted. If individuals in
making a statement reveal personal
VerDate Sep<11>2014
22:39 Oct 20, 2015
Jkt 238001
information (e.g., medical information)
about themselves, that information will
not usually be redacted. The CDC
Freedom of Information Act coordinator
will, however, review such revelations
in accordance with the Freedom of
Information Act and, if deemed
appropriate, will redact such
information. Disclosures of information
concerning third party medical
information will be redacted.
Contact Person for More Information:
Paul J. Middendorf, Ph.D., Designated
Federal Officer, NIOSH, CDC, 2400
Century Parkway NE., Mail Stop E–20,
Atlanta, GA 30345, telephone 1 (888)
982–4748; email: wtc-stac@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2015–26759 Filed 10–20–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting: Advisory Board on Radiation
and Worker Health (ABRWH or
Advisory Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), and pursuant to the
requirements of 42 CFR 83.15(a), the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the
aforementioned committee:
Times and Dates: 8:15 a.m.–5 p.m.,
Pacific Time, November 18, 2015. 8:15
a.m.–4:30 p.m., Pacific Time, November
19, 2015.
Public Comment Time and Date: 5
p.m.–6 p.m.*, Pacific Time, November
18, 2015.
* Please note that the public comment
period ends at the time indicated above
or following the last call for comments,
whichever is earlier. Members of the
public who wish to provide public
comments should plan to attend the
public comment session at the start time
listed.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
63791
Place: Waterfront Hotel, 10
Washington Street, Oakland, California
94607, Phone: 510–379–2652; Fax: 510–
832–6228. Audio Conference Call via
FTS Conferencing. The USA toll-free,
dial-in number is 1–866–659–0537 with
a pass code of 9933701. Live Meeting
CONNECTION: https://
www.livemeeting.com/cc/cdc/join?id
GS59T7&role=attend&pw=ABRWH;
Meeting ID: GS59T7; Entry Code:
ABRWH.
Status: Open to the public, limited
only by the space available. The meeting
space accommodates approximately 100
people.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to the CDC.
NIOSH implements this responsibility
for CDC. The charter was issued on
August 3, 2001, renewed at appropriate
intervals, and will expire on August 3,
2017.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters For Discussion: The agenda
for the Advisory Board meeting
E:\FR\FM\21OCN1.SGM
21OCN1
tkelley on DSK3SPTVN1PROD with NOTICES
63792
Federal Register / Vol. 80, No. 203 / Wednesday, October 21, 2015 / Notices
includes: NIOSH Program Update;
Department of Labor Program Update;
Department of Energy Program Update;
Report by the Dose Reconstruction
Review Methods Work Group; SEC
Petitions Update; Site Profile reviews
for: Dow Chemical Co. (Madison,
Illinois), and General Steel Industries
(Granite City, Illinois); SEC petitions for:
Battelle Laboratories, King Avenue
(1956–1970; Columbus, Ohio),
Lawrence Livermore National
Laboratory (1974–1995; Livermore,
California), Blockson Chemical Co.
(1960–1991; Joliet, Illinois), Rocky Flats
Plant (1984–1989; Golden, Colorado),
Idaho National Laboratory (1949–1970;
Scoville, Idaho), and Kansas City Plant
(1949–1993; Kansas City, Missouri); and
Board Work Sessions.
The agenda is subject to change as
priorities dictate.
In the event an individual cannot
attend, written comments may be
submitted to the contact person well in
advance of the meeting. Any written
comments received will be provided at
the meeting in accordance with the
redaction policy provided below.
Policy on Redaction of Board Meeting
Transcripts (Public Comment): (1) If a
person making a comment gives his or
her personal information, no attempt
will be made to redact the name;
however, NIOSH will redact other
personally identifiable information,
such as contact information, social
security numbers, case numbers, etc., of
the commenter.
(2) If an individual in making a
statement reveals personal information
(e.g., medical or employment
information) about themselves that
information will not usually be
redacted. The NIOSH Freedom of
Information Act (FOIA) coordinator
will, however, review such revelations
in accordance with the Federal
Advisory Committee Act and if deemed
appropriate, will redact such
information.
(3) If a commenter reveals personal
information concerning a living third
party, that information will be reviewed
by the NIOSH FOIA coordinator, and
upon determination, if deemed
appropriated, such information will be
redacted, unless the disclosure is made
by the third party’s authorized
representative under the Energy
Employees Occupational Illness
Compensation Program Act (EEOICPA)
program.
(4) In general, information concerning
a deceased third party may be disclosed;
however, such information will be
redacted if (a) the disclosure is made by
an individual other than the survivor
claimant, a parent, spouse, or child, or
VerDate Sep<11>2014
22:39 Oct 20, 2015
Jkt 238001
the authorized representative of the
deceased third party; (b) if it is unclear
whether the third party is living or
deceased; or (c) the information is
unrelated or irrelevant to the purpose of
the disclosure.
The Board will take reasonable steps
to ensure that individuals making
public comment are aware of the fact
that their comments (including their
name, if provided) will appear in a
transcript of the meeting posted on a
public Web site. Such reasonable steps
include: (a) A statement read at the start
of each public comment period stating
that transcripts will be posted and
names of speakers will not be redacted;
(b) A printed copy of the statement
mentioned in (a) above will be
displayed on the table where
individuals sign up to make public
comments; (c) A statement such as
outlined in (a) above will also appear
with the agenda for a Board Meeting
when it is posted on the NIOSH Web
site; (d) A statement such as in (a) above
will appear in the Federal Register
Notice that announces Board and
Subcommittee meetings.
Contact Person For More Information:
Theodore Katz, Designated Federal
Officer, NIOSH, CDC, 1600 Clifton Road
NE., MS E–20, Atlanta, Georgia 30333,
telephone: (513) 533–6800, toll free: 1–
800–CDC–INFO, email: dcas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2015–26757 Filed 10–20–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting: Clinical Laboratory
Improvement Advisory Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Times and Dates
8:30 a.m.–5 p.m.., November 18, 2015.
8:30 a.m.–12 p.m., November 19,
2015.
Place: CDC, 2500 Century Center
Boulevard, Rooms 1200/1201, Atlanta,
Georgia 30345.
Status: Open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people. This meeting will also be
webcast, please see information below.
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services (HHS); the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendment (CLIA)
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patientcenteredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of nonregulatory guidelines to accommodate
technological advances, such as new
test methods and the electronic
transmission of laboratory information.
Matters for Discussion: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
discussions will include laboratory
information exchange (interoperability);
noninvasive prenatal testing; CLIA
waiver guidance; the Institute of
Medicine (IOM) report ‘‘Improving
Diagnosis in Health Care;’’ and FDA
guidance for laboratory developed tests.
Agenda items are subject to change as
priorities dictate.
Webcast: The meeting will also be
webcast. Persons interested in viewing
the webcast can access information at:
https://
cdclabtraining.adobeconnect.com/
novcliac/.
Online Registration Required: All
people attending the CLIAC meeting inperson are required to register for the
meeting online at least 5 business days
in advance for U.S. citizens and at least
10 business days in advance for
E:\FR\FM\21OCN1.SGM
21OCN1
]]>Agencies
[Federal Register Volume 80, Number 203 (Wednesday, October 21, 2015)]
[Notices]
[Pages 63791-63792]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-26757]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meeting: Advisory Board on Radiation and Worker Health (ABRWH or
Advisory Board), National Institute for Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42
CFR 83.15(a), the Centers for Disease Control and Prevention (CDC),
announces the following meeting of the aforementioned committee:
Times and Dates: 8:15 a.m.-5 p.m., Pacific Time, November 18, 2015.
8:15 a.m.-4:30 p.m., Pacific Time, November 19, 2015.
Public Comment Time and Date: 5 p.m.-6 p.m.*, Pacific Time,
November 18, 2015.
* Please note that the public comment period ends at the time
indicated above or following the last call for comments, whichever is
earlier. Members of the public who wish to provide public comments
should plan to attend the public comment session at the start time
listed.
Place: Waterfront Hotel, 10 Washington Street, Oakland, California
94607, Phone: 510-379-2652; Fax: 510-832-6228. Audio Conference Call
via FTS Conferencing. The USA toll-free, dial-in number is 1-866-659-
0537 with a pass code of 9933701. Live Meeting CONNECTION: https://www.livemeeting.com/cc/cdc/join?id GS59T7&role=attend&pw=ABRWH; Meeting
ID: GS59T7; Entry Code: ABRWH.
Status: Open to the public, limited only by the space available.
The meeting space accommodates approximately 100 people.
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key functions of the Advisory Board include providing advice
on the development of probability of causation guidelines which have
been promulgated by the Department of Health and Human Services (HHS)
as a final rule; advice on methods of dose reconstruction which have
also been promulgated by HHS as a final rule; advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program; and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC).
In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to the CDC. NIOSH implements this
responsibility for CDC. The charter was issued on August 3, 2001,
renewed at appropriate intervals, and will expire on August 3, 2017.
Purpose: This Advisory Board is charged with (a) providing advice
to the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and (c) upon request by the Secretary, HHS,
advising the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class.
Matters For Discussion: The agenda for the Advisory Board meeting
[[Page 63792]]
includes: NIOSH Program Update; Department of Labor Program Update;
Department of Energy Program Update; Report by the Dose Reconstruction
Review Methods Work Group; SEC Petitions Update; Site Profile reviews
for: Dow Chemical Co. (Madison, Illinois), and General Steel Industries
(Granite City, Illinois); SEC petitions for: Battelle Laboratories,
King Avenue (1956-1970; Columbus, Ohio), Lawrence Livermore National
Laboratory (1974-1995; Livermore, California), Blockson Chemical Co.
(1960-1991; Joliet, Illinois), Rocky Flats Plant (1984-1989; Golden,
Colorado), Idaho National Laboratory (1949-1970; Scoville, Idaho), and
Kansas City Plant (1949-1993; Kansas City, Missouri); and Board Work
Sessions.
The agenda is subject to change as priorities dictate.
In the event an individual cannot attend, written comments may be
submitted to the contact person well in advance of the meeting. Any
written comments received will be provided at the meeting in accordance
with the redaction policy provided below.
Policy on Redaction of Board Meeting Transcripts (Public Comment):
(1) If a person making a comment gives his or her personal information,
no attempt will be made to redact the name; however, NIOSH will redact
other personally identifiable information, such as contact information,
social security numbers, case numbers, etc., of the commenter.
(2) If an individual in making a statement reveals personal
information (e.g., medical or employment information) about themselves
that information will not usually be redacted. The NIOSH Freedom of
Information Act (FOIA) coordinator will, however, review such
revelations in accordance with the Federal Advisory Committee Act and
if deemed appropriate, will redact such information.
(3) If a commenter reveals personal information concerning a living
third party, that information will be reviewed by the NIOSH FOIA
coordinator, and upon determination, if deemed appropriated, such
information will be redacted, unless the disclosure is made by the
third party's authorized representative under the Energy Employees
Occupational Illness Compensation Program Act (EEOICPA) program.
(4) In general, information concerning a deceased third party may
be disclosed; however, such information will be redacted if (a) the
disclosure is made by an individual other than the survivor claimant, a
parent, spouse, or child, or the authorized representative of the
deceased third party; (b) if it is unclear whether the third party is
living or deceased; or (c) the information is unrelated or irrelevant
to the purpose of the disclosure.
The Board will take reasonable steps to ensure that individuals
making public comment are aware of the fact that their comments
(including their name, if provided) will appear in a transcript of the
meeting posted on a public Web site. Such reasonable steps include: (a)
A statement read at the start of each public comment period stating
that transcripts will be posted and names of speakers will not be
redacted; (b) A printed copy of the statement mentioned in (a) above
will be displayed on the table where individuals sign up to make public
comments; (c) A statement such as outlined in (a) above will also
appear with the agenda for a Board Meeting when it is posted on the
NIOSH Web site; (d) A statement such as in (a) above will appear in the
Federal Register Notice that announces Board and Subcommittee meetings.
Contact Person For More Information: Theodore Katz, Designated
Federal Officer, NIOSH, CDC, 1600 Clifton Road NE., MS E-20, Atlanta,
Georgia 30333, telephone: (513) 533-6800, toll free: 1-800-CDC-INFO,
email: dcas@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2015-26757 Filed 10-20-15; 8:45 am]
BILLING CODE 4163-18-P
